2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …

N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of the American …, 2022 - jacc.org
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …

Writing Committee Members, SS Virani… - Journal of the American …, 2023 - jacc.org
Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Circulation, 2022 - Am Heart Assoc
Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice …

FLJ Visseren, F Mach, YM Smulders… - European heart …, 2021 - academic.oup.com
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

M Packer, SD Anker, J Butler, G Filippatos, JP Ferreira… - Circulation, 2021 - Am Heart Assoc
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …

Hallmarks of cardiovascular ageing

M Abdellatif, PP Rainer, S Sedej… - Nature Reviews …, 2023 - nature.com
Normal circulatory function is a key determinant of disease-free life expectancy (healthspan).
Indeed, pathologies affecting the cardiovascular system, which are growing in prevalence …

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …

J Knuuti, W Wijns, A Saraste, D Capodanno… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …